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Abstract: Oncolytic viruses are multifunctional anticancer agents with huge clinical potential, 
and have recently passed the randomized Phase III clinical trial hurdle. Both wild-type and 
engineered viruses have been selected for targeting of specific cancers, to elicit cytotoxic-
ity, and also to generate antitumor immunity. Single-agent oncolytic virotherapy treatments 
have resulted in modest effects in the clinic. There is increasing interest in their combination 
with cytotoxic agents, radiotherapy and immune-checkpoint inhibitors. Similarly to oncolytic 
viruses, the benefits of chemotherapeutic agents may be that they induce systemic antitumor 
immunity through the induction of immunogenic cell death of cancer cells. Combining these 
two treatment modalities has to date resulted in significant potential in vitro and in vivo syner-
gies through various mechanisms without any apparent additional toxicities. Chemotherapy 
has been and will continue to be integral to the management of advanced cancers. This review 
therefore focuses on the potential for a number of common cytotoxic agents to be combined 
with clinically relevant oncolytic viruses. In many cases, this combined approach has already 
advanced to the clinical trial arena.
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Introduction
The conventional cancer treatments of surgery, chemotherapy, and radiotherapy 
remain the mainstay of current therapeutic approaches to cancer. They have been 
used successfully in combination with one another in the neoadjuvant, concomitant, 
and adjuvant context for many years. However, despite their utility and curative 
potential, each modality has its limitations in terms of limited efficacy, significant 
toxicity, lack of durability of response, and in the case of chemotherapy the emer-
gence of drug resistance. In addition to the release of neoantigens after tumor-cell 
destruction, exposure of cancer cells to cytotoxic agents may induce innate and 
adaptive immune responses against the cancer in other ways. Certain modes of 
cancer cell death are associated with immunogenicity through the induction of 
immunogenic cell-death (ICD) proteins, such as calreticulin, HSP70, ATP, and 
HMGB proteins.1 A number of cytotoxic agents have been shown to induce ICD,2 
while others are capable of modulating the tumor microenvironment by reducing 
the function or number of suppressive immune cells (regulatory T cells [T
regs
] and 
myeloid-derived suppressor cells [MDSCs]) or generating inflammatory cytokines 
(Table 1).3–137 Tumors treated with chemotherapy have also been shown to be more 
sensitive to cytotoxic T-lymphocyte (CTL) killing.51 Most of the evidence for ICD has 
been derived from murine models of human cancer. Relatively little is known about 
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Table 1 Mechanisms of immunomodulation caused by chemotherapy (chemo) alone, and synergy seen when combined with oncolytic virus
Chemotherapy  
drug
Mechanism of immunomodulation caused by chemo alone Immunomodulation  
reference
Oncolytic virus– 
chemo synergy
Cyclophosphamide Triggers TRAiL CD8+ T cell-mediated apoptosis 3
Induces proinflammatory production/induction of ICD marker  
calreticulin/HMGB1
4–6
Decreased Treg function 7–9 10,11
CD8+ T cell-specific tumor activity 7
induces T-helper type 1 or 17 immunity 12 11
Decreases complement function 13
Suppression of immune cell types 14,15
inhibits or delays viral neutralization response 14–23
increases MDSCs 24,25
enhances DC function 26
Synergy, but unknown immune function, if any 27,28
Gemcitabine Decreases MDSCs 29 29–31
Decreases neutralizing antibodies 29 29
induces iCD marker calreticulin 4
induces iCD marker HMGB1 32,33
Depletes B cells 34 35
Synergy, but unknown immune function, if any 32,36–45
Bortezomib enhances DC function 46
iCD and DAMP release 14
Antitumoral immunity 47
CD8+ T cell-mediated inhibition of tumor growth 46
Synergy, but undefined immune function, if any 48,49
Doxorubicin induces iCD marker calreticulin 4 50
Granzyme B released by CTLs 51
induces type i iFN response 52
increases Treg cells and significantly decreases NK cells 53
Decreases B7-H1/PD-L1 from cell surface 54
Synergy, but undefined immune function, if any 55–59
Mitoxantrone Induces DC/T-cell tumor infiltrate 60
Releases ATP 60
ecto-CRT, ecto-HSP70, and HMGB1 61,62
Tumor antigen-specific CD8+ and CD4+ T-cell activity 60,63,64 65
enhances DC function 66
Temozolomide Decreases Treg function 67
Tumor-specific T-cell responses 68 68
Synergy, but undefined immune function, if any 69–74
Docetaxel Decreases MDSCs, increases CD8+ T cells 75
enhances DC function 75
Synergy, but unknown immune function, if any 76–82
Paclitaxel Granzyme B released by CTLs 83
induces iCD marker calreticulin 4
induces MHC 84
Decreases Treg function 85–87
induces T-helper type 1 immunity 12
Type i iFN and HMGB1 release in vitro 88
NK cells essential for strong synergy 10
Slows neutralizing antibodies (with carboplatin) 89
Synergy, but unknown immune function, if any 90–99
5-Fluorouracil CD8+ T cell-mediated apoptosis 100
induces carcinoembryonic antigen (CeA) 101
Decreases MDSCs 102
Synergy, but unknown immune function, if any 103–105
Cisplatin Decreases Treg function 106
CD8+ T cell-specific tumor activity 106
Granzyme B released by CTL 50
(Continued)
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the immunogenicity of chemotherapy in cancer patients. 
The combination of “immunogenic” or ICD-inducing 
chemotherapy with other anticancer treatment modalities 
capable of priming and/or propagating immune responses 
is now being evaluated. While the obvious candidates for 
combination are cancer vaccines, low doses of radiotherapy 
and immune-checkpoint inhibitors, there is an increasingly 
compelling case for combination of chemotherapy with 
oncolytic viruses (OVs).138
Despite being recognized as having the potential to 
treat cancer since the beginning of the 20th century, OVs 
are only now entering the clinical arena for certain can-
cers, following the successful evaluation of talimogene 
laherparepvec (T-vec) in malignant melanoma.139 OVs 
are live viruses that are selectively toxic to cancer cells. 
The basis of selectivity for cancer versus normal cells 
is based on cell entry (tumor cells expressing a receptor 
the virus uses to gain entry), impaired IFN response in 
cancer cells, or dysregulation in key signaling pathways, 
such as the RAS pathway, which would otherwise (eg, 
through the phosphorylation of PKR) allow the cell to 
negate the virus. Clinical trials involving OVs as single 
agents have largely been safe, demonstrated minimal tox-
icity, and in certain studies shown signs both of efficacy 
by radiological evaluation and the presence of live virus 
in tumor biopsies a week or more after treatment.140,141 
However, the overall efficacy of single-agent OV therapy 
has at best been modest. The true potential of OVs may 
yet be realized through their combination with other 
treatment modalities, such as chemotherapy. As well as 
synergistic mechanisms of tumor-cell killing, combina-
tion with chemotherapeutics through careful sequencing 
may help to overcome some of the barriers in the tumor 
microenvironment thought to limit the efficacy of OVs. 
These include large tumor size,142 poor vasculature,143 
elevated interstitial pressure,144 and physical barriers.145 
One potential limitation of OVs that is regularly debated 
is the rapid generation of antiviral antibody responses a 
week or so following OV administration. There have been 
attempts to attenuate this response using such agents as 
cyclophosphamide (CPA; discussed later), but it is clear 
that despite high levels of neutralizing antibodies, further 
administrations of the same OV can traffic to the tumor 
environment and cause tumor kill. The OV is most likely 
protected from neutralizing antibodies by carriage (hitch-
hiking) on granulocytes, lymphocytes, and platelets to 
tumor cells in metastatic deposits.146 Recent preclinical and 
clinical studies have shown that combining chemotherapy 
with OVs may potentially be highly synergistic, improving 
on the efficacy of each modality alone (Table 1).
In this review, we explore the many ways in which che-
motherapy and OVs have been considered in combination. 
The methods used by researchers have been based on 
cell lines using classical isobologram analysis, murine 
models, and in humans with a number of completed 
clinical trials.
Table 1 (Continued)
Chemotherapy  
drug
Mechanism of immunomodulation caused by chemo alone Immunomodulation  
reference
Oncolytic virus– 
chemo synergy
enhances DC function, cytokine release, and cytotoxic T-cell activation 107
Synergy, but unknown immune function, if any 108–118
Mitomycin C enhances DC function 71,119
Synergy, but unknown immune function, if any 120–124
Azadeoxycytidine enhances DC function 71
irinotecan Decreases Treg function 125
NK cells essential 126 126
Synergy, but unknown immune function, if any 126–129
Rapamycin/everolimus inhibition of T-cell proliferation 130 131
Decreases DC maturation 130
increases Treg cells 130
Decreases cellular iFN 132
Decreases cytokine release 131
Decreases antiviral antibody production 131,133
Synergy, but unknown immune function, if any 132–136
5-Aza induces cancer testis antigen 137
induces MHC 137
Abbreviations: iCD, immunogenic cell death; Treg, regulatory T cell; MDSCs, myeloid-derived suppressor cells; DC, dendritic cell; DAMP, danger-associated molecular pattern; 
CTLs, cytotoxic T lymphocytes; NK, natural killer; MHC, major histocompatibility complex; TRAiL, TNF-related apoptosis inducing ligand; ecto-CRT, ecto calreticulin.
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Cell-death mechanisms: 
immunogenic cell death is vital 
for cancer therapy
OV-mediated cell death does not fit exactly into one of the 
three classical categories of cell death (apoptosis, necrosis, 
and autophagy), and likewise cell-death pathways induced by 
chemotherapy can vary from agent to agent. Due to the physi-
ological consequences associated with cell death, enormous 
effort has been invested into understanding the three main 
mechanisms. Apoptosis is vital for development and the main-
tenance of tissue homeostasis, and is generally considered to be 
a nonimmunogenic form of cell death, while necrosis, which is 
less coordinated and results in the release of proinflammatory 
cytokines, has been regarded as immunogenic.147 However, it 
is now clear that the boundaries between each classical cell-
death pathway are not defined and there is often overlap. This 
has been demonstrated by the discovery of “immunogenic” 
apoptosis in tumor cells, which can be induced by specific 
chemotherapies, such as the anthracyclines and oxaliplatin 
(Figure 1).148,149 Similarly, OV-mediated cell death does not fit 
into either apoptosis or necrosis, but displays features of both, 
with variations between oncolytic viral types. In general, the 
immunogenic death (apoptosis, necrosis, autophagy, etc) of 
cancer cells involves a multistep process, beginning with the 
recognition of pathogen- associated molecular components, 
such as viral components, which cause such molecules as 
fractalkine, nucleotides, and ATP to be released, which in turn 
attract phagocytes or dendritic cells (DCs), and the expression 
of such signals as phosphatidylserine and calreticulin that aid 
recognition by phagocytes or DCs. Finally, danger-associated 
molecular patterns (DAMPs), such as HMGB1, are expressed. 
This enables dying tumor cells to lose the ability to induce 
tolerance and to stimulate powerful anticancer immune 
responses (Figure 1). Scientists have investigated many ways 
to increase the immunogenic effects seen with OVs, but it 
is becoming clearer that one way to complement the ICD 
mechanisms and the immunomodulatory effects (Table 1) 
seen with either therapy alone is to combine both OVs and 
chemotherapy to achieve either at least an additive or (even 
better) a synergistic result.
Combining chemotherapeutic  
drugs with OV therapy
Cyclophosphamide
CPA is an alkylating agent that causes cross-linking of DNA, 
and is used in the management of countless tumor types. 
Tumor-specific
T-cell priming
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Activating cytokines:
Type I IFN, TNF
Cancer cell
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Figure 1 A summary of immunogenic cell death (iCD) caused by oncolytic virus and/or chemotherapy.
Note: Reproduced from woller N, Gürlevik e, Ureche C-i, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccines. Front Oncol. 2014;4:188. doi: 10.3389/fonc. 
2014.00188.148
Abbreviations: Ads, adenoviruses; APCs, antigen-presenting cells; DAMPs, danger-associated molecular patterns; DCs, dendritic cells; dsRNA, double-stranded RNA; 
eGFR, epidermal growth factor receptor; eR, endoplasmic reticulum; HSV, herpes simplex virus; iFN, interferon; MV, measles virus; NDV, Newcastle disease virus; PAMPs, 
pathogen-associated molecular patterns; PRRs, pattern recognition receptors; PV, parvovirus; ROS, reactive oxygen species; ssRNA, single-stranded RNA; TAAs, tumor-
associated antigens; TNF, tumor necrosis factor; VV, vaccinia virus.
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In itself, CPA is not an active drug. It requires  metabolic 
 activation by aldehyde dehydrogenase, producing the active 
compound 4-hydroxycyclophosphamide. The release of 
HMGB1 and ecto-CRT is seen with CPA treatment, which 
results in DC activation, proinflammatory cytokine produc-
tion, and T-cell proliferation.5,6 Synergy in vivo has been 
shown using a variety of OVs and CPA, including herpes 
simplex virus (HSV)-1, adenovirus, vaccinia,27,28 reovirus, 
measles, myxoma virus,15 and vesicular stomatitis virus 
(VSV).23 The combination of CPA with reovirus has been 
investigated in in vivo models, and these studies have dem-
onstrated safety and efficacy using a carefully titrated CPA 
schedule, including administration 24 hours before reovi-
rus.20 However, significant normal-tissue toxicity was seen 
at higher doses, similar to the administration of reovirus to 
B-cell knockout mice.20 Therefore, careful titration of any 
immunomodulatory effect is required to optimize efficacy 
without augmenting viral replication and toxicity in normal 
tissues. Studies with oncolytic HSV-1 and adenovirus in 
combination with CPA have shown a fall in the magni-
tudes of antiviral immune cells, which prevents, inhibits, 
or delays viral neutralization.14,17,19,21 CPA has been shown 
in vivo to deplete the complement response to HSV.13 With 
oncolytic measles virus and VSV, CPA has been shown to 
strongly damp down the antiviral host immune response,23,150 
but in the case of a VSV combination resulted in reduced 
therapeutic efficacy compared to CPA alone.150 Zemp et al 
showed that the removal of the tumor-resident macrophage 
population in an orthotopic glioma model by CPA substan-
tially increased the survival of mice with myxoma virus 
post-treatment.15
Additional studies imply that a CPA/viral combination 
can also boost antitumor immunity by inhibiting T
regs
.10,11 
These data were confirmed in a Phase I clinical trial that 
showed that metronomic dosing of CPA decreased T
regs
 
in solid tumors treated with adenovirus granulocyte mac-
rophage colony-stimulating factor, without compromising 
the stimulation of antitumor responses.11 In contrast, Phase 
I clinical trials showed that reovirus (where CPA dose was 
escalated from 25 to 1,000 mg/m2) or Seneca Valley virus 
coadministration with CPA were safe, but did not attenuate 
host antiviral responses.151,152
Gemcitabine
Gemcitabine is a fluorinated deoxycytidine analog that has two 
forms: the gemcitabine diphosphate form, which impedes the 
ribonucleotide reductase enzyme, resulting in a reduction in the 
pool of deoxynucleotide available for DNA synthesis; whereas 
the second form, gemcitabine triphosphate, is incorporated into 
DNA, causing chain termination and resulting in apoptosis 
and cell death. Gemcitabine has also been shown to deplete 
MDSCs and promote  antitumor immune responses.153 Both 
gemcitabine and CPA can decrease neutralizing antibodies in 
cancer patients.29 An increase in antitumor activity was seen 
with a wide array of OVs in combination with gemcitabine, 
including adenovirus,38–44 parvovirus,32,33 reovirus,30,37 VSV,35 
HSV,31 vaccinia,45 and myxoma virus.36 Gemcitabine alone 
fails to trigger HMGB1 release; in contrast, parvovirus does 
induce HMGB1.32 Combination treatment of both parvovirus 
and gemcitabine results in a high level of tumor cytotoxicity 
without impeding ICD activities.32
In vivo studies with either HSV or reovirus in combi-
nation with gemcitabine improved the survival compared 
with either treatment alone.30,31 These therapeutic combina-
tions also demonstrate that gemcitabine limits the reovirus/
HSV-1-induced accumulation of MDSCs in the tumor 
microenvironment.30,31 Gemcitabine treatment in a Phase I 
clinical trial showed greatly reduced levels of reovirus-neu-
tralizing antibodies, and 80% of patients exhibited either a 
partial response or stable disease.29
Bortezomib
Bortezomib is a peptide-based, reversible proteasome inhibi-
tor. Potent immunomediated antitumor effects were seen 
after treatment with bortezomib in the form of enhanced 
DC function and upregulation of the HSP60 and HSP90 
proteins.46 Bortezomib has been shown to generate reac-
tive oxygen species, which are believed to cause ICD and 
DAMP release, increasing cellular stress.154–157 A number 
of OVs have been studied in combination with bortezomib, 
including HSV-1,60 reovirus,49 adenovirus,47 and VSV.48 Both 
HSV-1 and reovirus have shown synergy, but the contribution 
of immunomodulatory effects of bortezomib and antitumor 
immune responses in vivo was not examined.49,156 Combining 
VSV and bortezomib resulted in antagonism in vitro, but 
in contrast synergy was seen in vivo.48 This may have been 
due to immune cells in vivo that were not present in the 
in vitro setting. The authors of this study cited an ovarian 
tumor mouse study that showed reduction in tumor growth 
facilitated by CD8+ T-cell function with bortezomib alone.46 
In a hepatocellular carcinoma in vivo model, treatment with 
bortezomib and an adenovirus expressing human telomerase 
reverse-transcriptase resulted in caspase-dependent apoptosis 
and a reduction in the antiviral immune responses.47
Doxorubicin
Doxorubicin (Dox) is an anthracycline antibiotic that 
intercalates into the DNA double-helical structure. This 
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intercalation process hinders unwinding and resealing of 
DNA for transcription, and thus inhibits cellular DNA rep-
lication. Dox also stimulates the rapid production of type I 
IFNs by tumor cells after activation of TLR3, resulting in 
the release of chemokine (CXCL10).52 A type I IFN gene 
signature-predicted response to Dox therapy has been seen 
in breast cancer patients.52
These data suggest that Dox-mediated immune responses 
mimic those induced by viral pathogens. In addition to 
inducing ICD4 and type I IFN secretion, Dox and other che-
motherapeutics also increase the susceptibility of tumors to 
CTLs by increasing tumor-cell permeability to granzyme B 
released by the CTLs.51 The addition of Dox to adenovirus 
resulted in significantly increased expression of calreticulin 
in vitro.50 Synergy between Dox and other OVs, such as HSV-
1,55 measles,56 vaccinia,57 Coxsackie virus 21,50 and VSV59 
has been seen in vitro and in vivo, but no immunocomponent 
effects have yet been defined.
Mitoxantrone
Mitoxantrone (MTX) is a synthetic anthracenedione 
antineoplastic agent derived from the anthraquinone dye 
ametantrone,158 which is frequently used to manage prostate, 
leukemia, and breast cancer.159,160 It is structurally similar to 
Dox, with both drugs having a planar aromatic ring struc-
ture that enables them to interact with DNA by intercalation 
between base pairs. MTX can inhibit the activity of the 
nuclear enzyme DNA topoisomerase (II), interfere with RNA 
and cause the cross-linking of DNA and strand breaks, and 
produce reactive oxygen species. MTX is believed to lack 
cell-cycle phase specificity, because it has cytocidal effects 
on both proliferating and nonproliferating cells.161 MTX also 
has immunosuppressive properties, resulting in the inhibi-
tion of proinflammatory cytokines, such as TNF, IL-2, and 
IFNγ. It is therefore used in the management of multiple 
sclerosis.162 Cancer cells undergoing immunogenic apoptosis 
and autophagy after treatment with MTX express various 
DAMPs, such as ecto-HSP70, ATP, and HMGB-1,160,161 and 
stimulate the peripheral relocation of CRT.163 MTX treat-
ment also increases uptake of tumor-associated antigens 
by antigen-presenting cells, resulting in establishment of 
antitumor activity by antigen-specific CD8+ and CD4+ T 
cells.59,63,64 Both in murine models76,77 and in human patients 
with cancer,146 antitumor immune responses induced by 
cancer cells undergoing ICD are associated with better clini-
cal responses. A combination of HSV-1 with MTX failed to 
increase cytotoxicity or halt virus replication in vitro.65,164 In 
contrast, in vivo, the same combination provided significant 
survival benefit when administered locally to HER-2/neu 
subcutaneous tumors.65 This protective effect was facilitated 
by enhanced levels of tumor antigen-specific CTL cells and 
an increase in intratumoral infiltration of neutrophil cells.65 
These results were confirmed by depleting CD4-, CD8-, and 
Ly6G-expressing cells from the model, showing that these 
cells are essential for enhanced efficacy.65
irinotecan
Irinotecan is an antineoplastic enzyme inhibitor and shows 
activity against colorectal, lung, esophageal, and gastric 
cancers, leukemia, and lymphomas. Irinotecan inhibits the 
topoisomerase I-DNA complex and causes double-strand 
DNA breakage that results in cell death. In the clinic, irino-
tecan is used in combination with fluorouracil and leucovorin 
(FOLFIRI) in colon cancer patients.125 Treatment with the 
FOLFIRI combination significantly reduced the amount of 
CD4+FoxP3+ T
regs
 in patients, without altering the total number 
of lymphocytes or the population of CD4+ T lymphocytes.125 
Irinotecan has been shown to inhibit HSV-1 viral replication 
and lytic oncolysis in colon cancer cell lines.164 In contrast, 
other groups show synergy with OVs/irinotecan, including 
HSV-1 encoding CYP2B1,127 reovirus,128 and Sindbis virus.126 
However, only the study on Sindbis virus looked at immune 
components in irinotecan synergy, concluding that natural 
killer cells are essential for the process.126
Temozolomide
Temozolomide (TMZ) is an alkylating agent currently used 
as first-line therapy for glioma treatment, due to its DNA-
damaging effect.165,166 Advanced melanoma patients treated 
with low-dose TMZ followed by DC (autologous tumor 
lysate) vaccination showed a reduction in circulating immu-
nosuppressive FoxP3+ T
regs
.67
Synergy has been recorded between TMZ and both 
HSV69,71 and adenovirus.68,72–74 An unconventional patient 
study on various cancers treated with oncolytic adenovirus 
and a low dose of TMZ showed an upregulation of ICD 
signal HMGB1 and specific tumor T-cell responses, which 
resulted in disease control in 67%68 of cases. These results 
are interesting, but are difficult to interpret, due to the large 
number of different types of adenoviruses used in this study 
and differences in doses of TMZ.
Pi3K–Akt–mTOR pathway inhibitors
The PI3K–Akt–mTOR signaling cascade is well characterized 
and plays a crucial role in a variety of physiologic processes, 
including cell-cycle progression, differentiation, transcription, 
translation, apoptosis, motility, autophagy, anabolic pro-
cesses (including protein and lipid synthesis), and metabolic 
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 processes (including normal glucose homeostasis). Activation 
of the PI3k–Akt–mTOR signaling pathway is implicated in 
tumorigenesis, and PI3K–Akt–mTOR is the most frequently 
mutated pathway in cancer. PI3K/Akt inhibitors show synergy 
with HSV-MG18L71 and adenovirus ZD55-TRAIL166, but 
immunocomponents were not studied. mTOR is a master 
regulator of cellular translation and also impacts translation 
of viral proteins. Rapamycin is able to inhibit mTOR167,168 by 
forming a complex with FKBP12.141,169 This inhibits prolifera-
tion, which results in the induction of autophagy in cancer 
cells.130,170 T and B lymphocytes also show a decrease in cell 
function in the presence of rapamycin.171–175 Also, rapamycin 
exhibits significant antiangiogenesis and anticancer proper-
ties.133 Studies with an oncolytic HSV show that rapamycin 
enhances viral replication in vitro.134 A possible mechanism 
for this enhanced viral replication may be the reduction of 
cellular IFN, which has been seen with VSV/rapamycin in 
an in vivo glioma model.136 Studies with adenovirus have 
shown that rapamycin/everolimus can suppress the adenovirus 
innate response (TNF, IL-1β, IL-6, IL-8, IL-10, IL-12, and 
IFNδ) reduce T-cell infiltration and decrease anti-Ad anti-
body production and T-cell function.131,133 This suppression 
by rapamycin/everolimus of the host viral immune response 
may explain the improved efficacy of oncolytic HSV,134 
VSV,136 adenovirus,131,135 and myxoma virus15 in a number of 
in vivo models.
Mitomycin C
Mitomycins are a group of antineoplastic antibiotics, of 
which mitomycin C (MMC) is the most studied. MMC is 
an alkylating agent that cross-links DNA and is produced by 
Streptomyces caespitosus. Apoptosis can be induced by MMC, 
either by the caspase 3- and 8-dependent Fas–FasL pathway or 
via the activity of the NFκB pathway.176 MMC has also been 
shown to maintain innate and adaptive immune responses in 
a major subpopulation of human blood DCs (slan DC). This 
has encouraged the design of clinical trials for tumor patients 
that are based on the simultaneous administration of tumor 
antigen-loaded DCs and MMC.119 Intracellular adhesion mol-
ecule-1 and decay accelerating factor, the viral entry receptors 
for Coxsackie virus A21, have been shown to be upregulated 
in the presence of MMC, leading to synergy between virus 
and drug.120 HSV-1,121–123 vaccinia,124 and adenovirus177 have 
all shown synergy with MMC, but these studies have not 
identified any immune-function mechanism.
Docetaxel
Docetaxel (Doc) has been shown to have a number of inhibi-
tory functions on tumor cells, including inducing apoptosis, 
angiogenesis, and impeding gene-expression processes,178 
but its primary anticancer function is via microtubule stabi-
lization. Doc has been shown to decrease MDSCs and thus 
increase CD8+ T-cell activity in a murine model of breast 
cancer.179 Oncolytic adenovirus,76–79 reovirus,80,81 and HSV-182 
have all shown synergy with Doc, but these studies have not 
identified any immune-function mechanism. Doc had no 
effect on the production of neutralizing antibodies to reovirus 
in a Phase I clinical trial.81
5-Fluorouracil
5-Fluorouracil (5-FU) is an antimetabolite drug that inhibits 
the enzyme thymidylate synthase and the incorporation of 
its metabolites into RNA and DNA.180 5-FU did not suppress 
the production of neutralizing antibodies against G207, but 
increased viral spread in subcutaneous hamster gallbladder 
tumors.105 Antitumor effects of 5-FU are mediated, at least in 
part, by its selective cytotoxic action on MDSCs.102 Exposure 
of colon and pancreatic cancer cells to 5-FU significantly 
antagonizes both wild-type HSV-1 replication and lytic 
oncolysis.164 In contrast, an HSV-1 mutant missing one copy 
of its ICP0, ICP4, and ICP34.5 gene (NV1066) resulted in 
enhanced viral replication.
Cisplatin
Cisplatin is a well-characterized alkylating agent used for 
the management of a wide range of cancers. As with other 
alkylating agents, its main mode of action is its ability to 
cross-link with the purine bases on the DNA. Cisplatin also 
interferes with DNA-repair mechanisms, which causes DNA 
damage, and subsequently induces apoptosis in tumor cells.181 
Cisplatin can decrease T
regs
 and enhance antigen-specific 
CD8+ T-cell activity in murine models,106 and almost com-
pletely abrogate the inflammatory cytokine gene upregulation 
induced by reovirus.115 In contrast, a parvovirus–cisplatin 
combination induced higher cytokine release than either 
agent alone, and also resulted in pronounced DC maturation 
and cytotoxic T-cell activation.107
Discussion
OVs have been shown to be safely combined with conventional 
cytotoxic agents and evaluation in clinical trials justified on the 
basis of potential synergy through direct cytotoxicity, indirect 
immunogenicity, and/or alteration of the tumor microenvi-
ronment. The number of agents in clinical trials reflects the 
potential for this approach, which has recently focused away 
from delivery of live viruses to tumor sites, tumor lysis, and 
debulking to the induction of antitumor immunity through 
local induction of ICD, which ultimately will result in abscopal 
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effects on distant metastases. Although not yet formally 
addressed in studies, there would most likely be low likelihood 
of cross-resistance to either treatment modality.
A number of human studies have already exploited 
this potential, as exemplified by the US Food and Drug 
Administration approval of the agent T-Vec for the treat-
ment of malignant melanoma. Ongoing human studies are 
 evaluating both DNA and RNA viruses and wild-type agents, 
as well as modified agents expressing immunostimulatory 
gene products. Combination with immune-checkpoint inhibi-
tors has swiftly followed, with signals already of increased 
response rates compared to virus or checkpoint inhibitor 
alone.182 This follows evidence in a preclinical in vivo 
melanoma model, the oncolytic Newcastle disease virus, in 
combination with an anti-CTLA-4 antibody (ipilimumab), 
that showed enhanced tumor infiltration by activated CD8+ 
and CD4+ T cells and a reduction in T
regs
.183 This model also 
showed a nearly 70% rate of cure with combination treat-
ment compared to less than 25% for agents alone. Prolonged 
survival was also seen in the same in vivo melanoma model 
(B16.F10) when treated with a combination of anti PD-1 
antibody and reovirus.184 It is most likely that in the near 
future, combination studies with OVs will focus largely on 
immune-checkpoint modulation, but this may be tempered 
in term of toxicities and high cost.
While the earliest combination studies of OVs with chemo-
therapeutic agents were focused on attenuation of the expected 
brisk neutralizing antiviral antibody response, there is huge 
potential for combinations based on the immunostimulatory 
effects of common cytotoxic agents. Recent studies have 
shown convincingly that many OVs can hitchhike on circulat-
ing blood cells, are protected from neutralizing antibodies, 
and reach tumor sites, so this end point of chemotherapy–
OV combination is now being considered less important. A 
key factor that may allow combination studies to evolve is 
that almost all human OV studies have been associated with 
minimal toxicity, and actual dose-limiting toxicities rarely 
achieved. Therefore, patients will not be expected to face new 
and additional side effects and lower quality of life beyond 
the known chemotherapeutic agent-toxicity profile.
Historically, chemotherapy has been thought to prompt 
cancer cell death in an immunogenically silent way, but 
extensive studies have shown that such treatment can 
induce humoral and cellular antitumor immunity and break 
immune tolerance to tumors. The more subtle detail of 
this potential centers around the dose and sequencing of 
agents: CPA is myelosuppressive at conventional doses, but 
immunomodulatory as a single dose in combination with 
 immunotherapy, or may be used to delete T
regs
 by metronomic 
dosing. Furthermore, combination studies will logically 
exploit the natural tropism of certain OVs for tumor vas-
culature with chemotherapeutic agents with antiangiogenic 
potential or those that may cause vascular leakage to allow 
OV into that tumor microenvironment.185
There is huge potential for the combination of OVs with 
chemotherapeutics, but success will entail careful selection 
of the OV, the tumor model, the molecular dysregulation har-
bored by the malignancy, and the transgenes the OV carries, 
together with the best dose and sequencing with the most 
appropriate cytotoxic. The ideal disease setting and virus is 
not clear as yet, and further challenges will be evaluation of 
response to combination therapy and the contribution of an 
OV added to a classical three-drug regimen in a common 
setting, such as advanced breast or gastrointestinal cancers. 
Our wealth of experience with single- and multiagent chemo-
therapy regimens at least allows us a head start with clinical 
translation of combinations with OVs.
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